edotreotide
Sign in to saveAlso known as SMT487
Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. When used therapeutically it is an example of peptide receptor radionuclide therapy.
Research
245 papers- Edotreotide Gallium Ga-68.2006
- A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).BMC cancer · 2025
- Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors.Cancer control : journal of the Moffitt Cancer Center · 2023
- Systematic review and meta-analysis of the efficacy and safety of [(177)Lu]Lu-edotreotide ([(177)Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.Journal of neuroendocrinology · 2026
- 90Y-edotreotide for metastatic carcinoid refractory to octreotide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010
via PubMed
~1 min read
Encyclopedic overview
4 sectionsContents
- Yttrium-90
- Lutetium-177
- See also
- References
Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. When used therapeutically it is an example of peptide receptor radionuclide therapy.
==Yttrium-90==
Excerpted from Wikipedia’s “edotreotide” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0